186 related articles for article (PubMed ID: 35817406)
21. Diagnostic and prognostic values of endothelial-cell-specific molecule-1 with malignant pleural effusions in patients with non-small cell lung cancer.
Lu GJ; Shao CJ; Zhang Y; Wei YY; Xie WP; Kong H
Oncotarget; 2017 Jul; 8(30):49217-49223. PubMed ID: 28514746
[TBL] [Abstract][Full Text] [Related]
22. Diagnostic value of soluble B7-H4 and carcinoembryonic antigen in distinguishing malignant from benign pleural effusion.
Jing X; Wei F; Li J; Dai L; Wang X; Jia L; Wang H; An L; Yang Y; Zhang G; Cheng Z
Clin Respir J; 2018 Mar; 12(3):986-990. PubMed ID: 28127951
[TBL] [Abstract][Full Text] [Related]
23. Pro-cathepsin D as a diagnostic marker in differentiating malignant from benign pleural effusion: a retrospective cohort study.
Choi H; Ko Y; Lee CY
BMC Cancer; 2020 Aug; 20(1):825. PubMed ID: 32867726
[TBL] [Abstract][Full Text] [Related]
24. Validity of procalcitonin and C-reactive protein measurement when differentiating between benign and malignant pleural effusion.
Botana-Rial M; Casado-Rey P; Leiro-Fernández V; Andrade-Olivié M; Represas-Represas C; Fernández-Villar A
Clin Lab; 2011; 57(5-6):373-8. PubMed ID: 21755828
[TBL] [Abstract][Full Text] [Related]
25. Developing a Prediction Score for the Diagnosis of Malignant Pleural Effusion: MPE Score.
Chantharakhit C; Sujaritvanichpong N
Asian Pac J Cancer Prev; 2022 Jan; 23(1):25-31. PubMed ID: 35092368
[TBL] [Abstract][Full Text] [Related]
26. Combination of DNA ploidy analysis and miR-21 or miR-24 in screening malignant pleural effusion.
Liu C; Huang L; Zhang X; Yang J
Interact Cardiovasc Thorac Surg; 2018 Mar; 26(3):376-381. PubMed ID: 29069463
[TBL] [Abstract][Full Text] [Related]
27. Quantitative proteomics revealed protein biomarkers to distinguish malignant pleural effusion from benign pleural effusion.
Dong T; Liang Y; Chen H; Li Y; Li Z; Gao X
J Proteomics; 2024 Jun; 302():105201. PubMed ID: 38768894
[TBL] [Abstract][Full Text] [Related]
28. Assessment of a panel of miRNAs in serum and pleural fluid for the differential diagnosis of malignant and benign pleural effusion.
Zhu LR; Yuan RX; Xia XB; Wang Y; Zhu YM; Fi L; Li J
Cancer Biomark; 2022; 33(1):71-82. PubMed ID: 34366325
[TBL] [Abstract][Full Text] [Related]
29. Diagnostic value of soluble receptor-binding cancer antigen expressed on SiSo cells and carcinoembryonic antigen in differentiating malignant from benign pleural effusion.
Dong J; Sun G; Zhu H
Tumour Biol; 2016 Mar; 37(3):3257-64. PubMed ID: 26438059
[TBL] [Abstract][Full Text] [Related]
30. Identification and diagnostic value of pleural fluid periostin and serum periostin of malignant pleural effusions in patients with non-small-cell lung cancer.
Wang J; Fu J; Shen Q; Zhang F; Wang Y; Wu LL
J Clin Lab Anal; 2019 Sep; 33(7):e22943. PubMed ID: 31268191
[TBL] [Abstract][Full Text] [Related]
31. Long-term stability of pleural fluid carcinoembryonic antigen and its effect on the diagnostic accuracy for malignant pleural effusion.
Yang DN; Niu Y; Wen JX; Wen XH; Wang YF; Yan L; Jiang TW; Huang JH; Chen H; Lippi G; Zheng WQ; Hu ZD
Thorac Cancer; 2023 Jul; 14(21):2077-2084. PubMed ID: 37314828
[TBL] [Abstract][Full Text] [Related]
32. A Novel Combination of Calprotectin and CXCL12 for Predicting Malignancy in Patients with Exudative Pleural Effusion.
Luo J; Wang M; Li C; Liang B; Liu D; Shi C; Jiang F; Wang T; Li P; Liang Z
Medicine (Baltimore); 2015 Nov; 94(47):e2105. PubMed ID: 26632726
[TBL] [Abstract][Full Text] [Related]
33. Diagnostic performance of CTLA-4, carcinoembryonic antigen and CYFRA 21-1 for malignant pleural effusion.
Chen M; Xie S; Wan C; Zeng N; Wu Y; Qin J; Shen Y; Wen F
Postgrad Med; 2017 Aug; 129(6):644-648. PubMed ID: 28506100
[TBL] [Abstract][Full Text] [Related]
34. Clinical value of jointly detection pleural fluid Midkine, pleural fluid adenosine deaminase, and pleural fluid carbohydrate antigen 125 in the identification of nonsmall cell lung cancer-associated malignant pleural effusion.
Zhang F; Wang J; Zheng X; Hu L; Chen J; Jiang F; Wang Y
J Clin Lab Anal; 2018 Oct; 32(8):e22576. PubMed ID: 29797475
[TBL] [Abstract][Full Text] [Related]
35. Diagnostic value of survivin for malignant pleural effusion: a clinical study and meta-analysis.
Tian P; Shen Y; Wan C; Yang T; An J; Yi Q; Chen L; Wang T; Wang Y; Wen F
Int J Clin Exp Pathol; 2014; 7(9):5880-7. PubMed ID: 25337230
[TBL] [Abstract][Full Text] [Related]
36. Validation of Calprotectin As a Novel Biomarker For The Diagnosis of Pleural Effusion: a Multicentre Trial.
Botana-Rial M; Vázquez-Iglesias L; Casado-Rey P; Cadena MP; Andrade-Olivié MA; Abal-Arca J; García-Nimo L; Ferreiro-Fernández L; Valdés-Cuadrado L; San-José ME; Rodríguez-Berrocal FJ; Fernández-Villar A
Sci Rep; 2020 Mar; 10(1):5679. PubMed ID: 32231227
[TBL] [Abstract][Full Text] [Related]
37. Laboratory Discrimination Between Neutrophilic Malignant and Parapneumonic Pleural Effusions.
Lee J; Lee YH; Seo H; Lee H; Kim YK; Yoo SS; Lee SY; Cha SI; Park JY; Kim CH
Am J Med Sci; 2019 Aug; 358(2):115-120. PubMed ID: 31331448
[TBL] [Abstract][Full Text] [Related]
38. Diagnostic value of tumor markers for lung adenocarcinoma-associated malignant pleural effusion: a validation study and meta-analysis.
Feng M; Zhu J; Liang L; Zeng N; Wu Y; Wan C; Shen Y; Wen F
Int J Clin Oncol; 2017 Apr; 22(2):283-290. PubMed ID: 27990560
[TBL] [Abstract][Full Text] [Related]
39. Auxiliary diagnostic value of tumor biomarkers in pleural fluid for lung cancer-associated malignant pleural effusion.
Zhang H; Li C; Hu F; Zhang X; Shen Y; Chen Y; Li F
Respir Res; 2020 Oct; 21(1):284. PubMed ID: 33121490
[TBL] [Abstract][Full Text] [Related]
40. Measurement and immunophenotyping of pleural fluid EpCAM-positive cells and clusters for the management of non-small cell lung cancer patients.
Thompson JC; Fan R; Black T; Yu GH; Savitch SL; Chien A; Yee SS; Sen M; Hwang WT; Katz SI; Feldman M; Vachani A; Carpenter EL
Lung Cancer; 2019 Jan; 127():25-33. PubMed ID: 30642547
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
